Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 20/20 | 0.49 |
| ▸ | MAP4K1 | Q92918 | 15/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18360230 | 0.96 | KLKB1 (0.55) | KLKB1MAP4K1 | |
| SCHEMBL18360360 | 0.91 | KLKB1 (0.50) | KLKB1MAP4K1 | |
| SCHEMBL18360093 | 0.90 | KLKB1 (0.51) | KLKB1MAP4K1 | |
| SCHEMBL18360294 | 0.87 | KLKB1 (0.49) | KLKB1MAP4K1 | |
| SCHEMBL18360295 | 0.86 | KLKB1 (0.51) | KLKB1MAP4K1 | |
| SCHEMBL18360263 | 0.86 | KLKB1 (0.55) | KLKB1MAP4K1 | |
| SCHEMBL18360072 | 0.85 | KLKB1 (0.52) | KLKB1MAP4K1 | |
| SCHEMBL18360254 | 0.85 | KLKB1 (0.49) | KLKB1MAP4K1 | |
| SCHEMBL18360261 | 0.85 | KLKB1 (0.50) | KLKB1MAP4K1 | |
| SCHEMBL18360345 | 0.83 | KLKB1 (0.56) | KLKB1MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981893-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2021-04-20 | — | — | US | claimed |
| US-20190263783-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2019-08-29 | — | — | US | claimed |
| US-10981893-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20190263783-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2019-08-29 | — | — | US | disclosed |
| WO-2017001926-A2 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC (BB) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981893-B2 | Therapeutic inhibitory compounds | SERPINB1, KLKB1, SERPINE1 | KLKB1 2/4885MAP4K1 271/4885 |
| US-20190263783-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | SERPINB1, KLKB1, SERPINE1 | KLKB1 2/4885MAP4K1 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.